I don't understand this POV at all: you are saying that there is not enough data to determine efficacy in the subgroups even though the company is publishing efficacy numbers for the subgroups? You seem to be suggesting that the EMA simply doesn't have enough to work with. That is possible and can appreciate your position.
Market Data 
Markets 
AI
